Kallmann Syndrome
- GTR Test IDHelpEach Test is a specific, orderable test from a particular laboratory, and is assigned a unique GTR accession number. The format is GTR00000001.1, with a leading prefix 'GTR' followed by 8 digits, a period, then 1 or more digits representing the version. When a laboratory updates a registered test, a new version number is assigned.: GTR000278766.10
- Last updated: 2024-07-31
- Test version history
- 278766.10, last updated: 2024-07-31
- 278766.9, last updated: 2023-08-04
- 278766.8, last updated: 2022-08-18
- 278766.7, last updated: 2021-08-17
- 278766.6, last updated: 2020-08-25
- 278766.5, last updated: 2019-09-06
- 278766.4, last updated: 2019-02-15
- 278766.3, last updated: 2014-05-29
- 278766.2, last updated: 2014-03-24
- 278766.1, last updated: 2014-03-24
Research testHelpIn the U.S., clinical tests must be performed under CLIA certification. When a lab uses the same methods for a test in both clinical and research settings, the test appears as two separate GTR records. for Hypogonadotropic hypogonadism 7 with or without anosmia
Offered by MGH Harvard Center for Reproductive Medicine
Overview
Test name
HelpThe name the laboratory assigns the test. Used as the default title of the page specific to the test.Kallmann Syndrome (KS)
Purpose of the test
HelpIf the test is being performed for the purpose of contributing to generalizable knowledge, then in general, the intent is to publish the study results and a research ethics committee (e.g., IRB) will have reviewed the study protocol. If the test being performed so the lab can generate data to make technical improvements to a test, there may not be a protocol available for review.Contribute to generalizable knowledge
Click Condition tab for more information.
Methodology
HelpThe assay's major method category (biochemical, cytogenetic or molecular genetics); method category (i.e. enzyme assay, chromosome breakage studies, targeted mutation analysis); methodology (i.e. the name of the method used) and instruments used when performing this test.- Molecular Genetics
- CSequence analysis of the entire coding region
- Bi-directional Sanger Sequence Analysis
Researchers
| Person responsible for the studyHelpName of the principal investigator or lab director who is ultimately responsible for the conduct of the research. | Stephanie Seminara, MD, Scientific Director |
|---|---|
| Study contactHelpThe person designated as the point of contact to answer questions about the study and coordinate enrollment. | Research Coordinator, Staff, reproendogenetics@mgh.harvard.edu, 617-726-1309 (phone), 617-726-5357 (fax) |
| Co-investigatorHelpName of an individual(s) involved with the Principal investigator in the scientific development or execution of the research project. | Margaret Lippincott, MD, Lab Associate Director Ravikumar Balasubramanian, PhD, MD, Lab Associate Director |
- OMIM
- View AXL variations in ClinVar
- View DUSP6 variations in ClinVar
- View GNRH1 variations in ClinVar
- View GNRHR variations in ClinVar
- View FGF17 variations in ClinVar
- View SEMA3E variations in ClinVar
- View SRA1 variations in ClinVar
- View WDR11 variations in ClinVar
- View SPRY4 variations in ClinVar
- View CCDC141 variations in ClinVar
- View FEZF1 variations in ClinVar
- RefSeqGene
- Coriell Institute for Medical Research
IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.